Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

1. A lawsuit has been filed against Intellia Therapeutics, Inc. (NTLA). 2. Investors claim misleading statements regarding the viability of NTLA-3001 development. 3. Concerns grow over the cost and efficiency of viral-based editing methods. 4. Plaintiffs argue Intellia overestimated timelines for NTLA-3001 trials. 5. Shareholders Foundation is facilitating communication for affected investors.

Legal

75

4m saved

Insight

Article

FAQ

Why Very Bearish?

Litigation can significantly affect investor sentiment and market perception, as seen previously with other biotech firms facing lawsuits where stock prices dropped sharply amid legal complications.

How important is it?

The ongoing lawsuit addresses critical issues surrounding NTLA's product viability and investor trust, which are essential for the company's stock performance.

Why Short Term?

Initial investor reactions to lawsuits often lead to immediate sell-offs, as seen in past cases like that of Intellia's competitor, CRISPR Therapeutics, which faced similar litigation issues.

Related Companies

CRSP EDIT SGMO

SAN DIEGO, April 23, 2025

PRNewswire -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA).

Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) prior to July 2024 and continue to hold any of those NASDAQ: NTLA shares also have certain options and can contact the Shareholders Foundation at [email protected] or call +1(858) 779-1554.

On February 11, 2025, a NASDAQ: NTLA investor filed a lawsuit against Intellia Therapeutics, Inc. over alleged violations of securities laws. The plaintiff alleged that between July 30, 2024 and January 08, 2025, the defendants made false and/or misleading statements and/or failed to disclose that the defendants created the false impression that they possessed reliable information pertaining to the viability of NTLA-3001's development and eventual marketing, if approved, that Intellia's optimistic reports of timelines, including dosing and future studies of the drug, fell short of reality; the NTLA program was not viable or sustainable for Intellia because viral-based editing programs remained expensive and inefficient in comparison to then-existing non-viral delivery methods, that Intellia was not equipped to timely dose patients with NTLA-3001, maintain the drug's research and development, or even to maintain its full staff in light of the existing scientific landscape surrounding viral-based editing drugs, and that even if NTLA-3001 proved successful, the use of viral-based editing drugs is costly, inefficient, and poor mitigators of adverse effects in patients.

Those who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) should contact the Shareholders Foundation, Inc.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal-related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

SOURCE Shareholders Foundation, Inc.